Skip to main content

Corlanor FDA Approval History

FDA Approved: Yes (First approved April 15, 2015)
Brand name: Corlanor
Generic name: ivabradine
Dosage form: Tablets and Oral Solution
Company: Amgen Inc.
Treatment for: Heart Failure

Corlanor (ivabradine) is a hyperpolarization-activated cyclic nucleotide-gated channel blocker indicated for the treatment of chronic heart failure.

Development timeline for Corlanor

Apr 15, 2015Approval FDA Approves Corlanor (ivabradine) to Treat Heart Failure
Aug 27, 2014FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.